These include Ras signaling, ErbB signaling, NSCLC, AML, pancreatic cancer, colorectal cancer, and renal cancer as a result of treatment resistance mechanisms from the BRAF/MEK/PI3K axis [10]. This evidence concerns the gene EGFR and pancreatic neoplasm.